Decitabine and Cedazuridine | Aplastic Anemia & MDS International Foundation Return to top.

Decitabine and Cedazuridine

Brand name: 
Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)

INQOVI®  for adult patients with MDS or CMML who are intermediate-1, intermediate-2, and high-risk IPSS groups.  It is a prescribed oral tablet combination of decitabine and cedazurine approved by the FDA for adult patients with myelodysplastic syndromes (MDS) and patients with chronic myelomonocytic leukemia (CMML) including:

  • previously treated and untreated, de novo and secondary MDS including the following subtypes (refractory anemia, refractory anemia with ringed sideroblasts, fractory anemia and excess blasts and CMML) and,
  • intermediate-1, intermediate-2, and high risk IPSS groups.

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Share with